NASDAQ:CARM Carisma Therapeutics Q3 2024 Earnings Results & Report $0.0005 0.00 (0.00%) As of 12:25 PM Eastern Carisma Therapeutics met analyst earnings expectations in its Q3 2024 results, released November 7, 2024. The company reported EPS of -$0.31 versus the -$0.31 consensus estimate, while revenue was $3.39 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2024Report DateNovember 7, 2024Conference Call DateNovember 6, 2024Conference Call6:00 PM ET Carisma Therapeutics EPS ResultsActual EPS-$0.31Consensus EPS -$0.31Beat/MissMet ExpectationsOne Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersCarisma Therapeutics Revenue ResultsActual Revenue$3.39 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsCarisma Therapeutics' next earnings date is estimated for Thursday, November 5, 2026, based on past reporting schedules. Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Carisma Therapeutics Q3 2024 Earnings FAQ Did Carisma Therapeutics beat earnings estimates for Q3 2024? Carisma Therapeutics (NASDAQ:CARM) reported earnings of -$0.31 per share for Q3 2024, matching the consensus estimate of -$0.31. The report was announced on Thursday, November 7, 2024. What was Carisma Therapeutics' revenue for Q3 2024? Carisma Therapeutics reported revenue of $3.39 million for Q3 2024. When is Carisma Therapeutics' next earnings date? Carisma Therapeutics' next earnings date is estimated for Thursday, November 5, 2026. MarketBeat tracks confirmed and estimated earnings dates for Carisma Therapeutics on the company's earnings history page. Carisma Therapeutics Earnings HeadlinesCarmila: 2025 Annual ResultsFebruary 18, 2026 | businesswire.comCarisma Therapeutics announces Nasdaq delisting, SEC deregistrationDecember 6, 2025 | msn.com$169 Private Jet Trick ExposedFor $169, a growing circle of travelers are booking private jets without the wait, the hassle, or the high price tag. Travel writer Jennifer Stevens reveals the trick in her new book, Secrets Travel Writers Never Share, packed with 101 ways to fly, dine and stay like a VIP for less, including $32 five-star hotel stays and $26 Michelin-star meals.October 8 at 1:00 AM | International Living (Ad)Carisma Announces Delisting from Nasdaq and SEC DeregistrationDecember 5, 2025 | prnewswire.comCarisma Therapeutics Announces Executive Terminations and Wind-DownOctober 17, 2025 | msn.comCarisma Therapeutics stock plunges after Nasdaq delisting noticeOctober 10, 2025 | investing.comSee More Carisma Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Carisma Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Carisma Therapeutics and other key companies, straight to your email. Email Address About Carisma TherapeuticsCarisma Therapeutics (NASDAQ:CARM), Inc. is a clinical-stage biotechnology company focused on developing engineered macrophage and monocyte therapies for cancer and other serious diseases. Its approach is designed to harness the natural ability of these immune cells to locate and interact with disease sites while enhancing their ability to recognize and attack abnormal cells. The company’s technology platform uses genetic engineering to create targeted cell therapies, including chimeric antigen receptor macrophage (CAR-M) candidates. Carisma’s programs are intended to address tumors that may be difficult for conventional immune-cell therapies to reach or treat, including solid tumors. Its lead programs have focused on HER2-targeted therapies, such as CT-0525, an investigational CAR-monocyte therapy being evaluated in clinical development. Carisma Therapeutics was founded through research associated with the University of Pennsylvania and has established operations in Philadelphia. The company became publicly traded on the Nasdaq under the symbol CARM in 2023. Its leadership has included Steven Kelly as chief executive officer. Carisma’s research and development activities are primarily focused on advancing its macrophage-based immunotherapy platform and clinical pipeline.View Carisma Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Levi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsPepsiCo Stock Looks Poised to Bottom With High Yield, Deep ValueSkydance Just Became a Media Giant—With an $80 Billion Debt LoadConstellation Brands Beat Earnings, But Beer Demand Is Still a ProblemTesla's EV Delivery Beat Is In, So What Happens Now?BigBear.ai Is Heavily Shorted—and Its Fundamentals Are Starting to ChangePenguin Solutions Is Soaring as AI Memory Demand Explodes Upcoming Earnings Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
